Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults
Geoffrey J. Gorse(Saint Louis University), Nina D. Russell(New York Blood Center), Brian Livingston, Guido Ferrari(Duke University), Margaret Wecker, Mark J. Newman(City Of Hope National Medical Center), Lindsey R. Baden(Brigham and Women's Hospital), Tonya Villafana(AstraZeneca (Netherlands)), Hongli Li(Army Medical University), Elizabeth Noonan(Fred Hutch Cancer Center), Kent J. Weinhold(Duke Medical Center)
Cited by 59
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981
Influence of Human Immunodeficiency Virus Infection on the Course of Hepatitis C Virus Infection: A Meta‐Analysis
|Clinical Infectious Diseases|2001|969